Breadcrumb Navigation:

Home > About MS > Treatments

Treatments

Although there is still no cure for MS, effective strategies are available to modify the disease course, treat exacerbations (also called attacks, relapses, or flare-ups), manage symptoms, improve function and safety, and provide emotional support. In combination, these treatments enhance the quality of life for people living with MS.

Modifying the Disease Course

The following agents can reduce disease activity and disease progression for many individuals with relapsing forms of MS, including those with secondary progressive disease who continue to have relapses.

FDA-Approved Disease-Modifying Agents
Avonex (interferon beta-1a)
Betaseron (interferon beta-1b)
Copaxone (glatiramer acetate)
Novantrone (mitoxantrone)
Rebif (interferon beta-1a)
Tysabri (natalizumab)
  • Disease Management Consensus Statement (.pdf)
    Recommendations and principles from the Society’s National Clinical Advisory Board for health care professionals and people with MS—to guide treatment with the disease-modifying drugs.
     
  • The Disease-Modifying Drugs (.pdf)
    A booklet describing the approved use, dosage and route of delivery, side effects, benefits, and available support programs.
     
  • Patient Assistance Programs
    A listing of the pharmaceutical company financial assistance programs to help manage the costs of the drugs.
     
  • Treatment Locations
    These clinical facilities have a formal affiliation with the National MS Society. The appropriate chapter clinical advisory committee, composed of MS experts, has reviewed and approved the affiliation.
     

Treating Exacerbations

An exacerbation of MS is caused by inflammation in the central nervous system (CNS) that causes damage to the myelin and slows or blocks the transmission of nerve impulses. To be a true exacerbation, the attack must last at least 24 hours and be separated from a previous exacerbation by at least 30 days. However, most exacerbations last from a few days to several weeks or even months. Exacerbations can be mild or severe enough to interfere with a person’s ability to function at home and at work. Severe exacerbations are most commonly treated with high-dose corticosteroids to reduce the inflammation.

Managing Symptoms

Symptoms of MS are highly variable from person to person and from time to time in the same individual. While symptoms can range from mild to severe, most can be successfully managed with strategies that include medication, self-care techniques, rehabilitation (with a physical or occupation therapist, speech/language pathologist, cognitive remediation specialist, among others), and the use of assistive devices.

Promoting Function through Rehabilitation

Rehabilitation programs focus on function—they are designed to help you improve or maintain your ability to perform effectively and safely at home and at work. Rehabilitation professionals focus on overall fitness and energy management, while addressing problems with accessibility and mobility, speech and swallowing, and memory and other cognitive functions.

Rehabilitation is an important component of comprehensive, quality health care for people with MS, at all stages of the disease. Rehabilitation programs include:

  • Physical Therapy 
  • Occupational Therapy 
  • Therapy for Speech and Swallowing Problems 
  • Cognitive Rehabilitation 
  • Vocational Rehabilitation 

The Role of Complementary and Alternative Medicine (CAM)

CAM includes everything from exercise and diet to food supplements, stress management strategies, and lifestyle changes. These therapies come from various disciplines and traditions—yoga, hypnosis, relaxation techniques, traditional herbal healing, Chinese medicine, macrobiotics, naturopathy, and many others. They are referred to as complementary when they are used in conjunction with conventional medical treatments and alternative when they are used instead of conventional treatments.

Treatment Updates

Bayer HealthCare Pharmaceuticals Launching New Needle for Betaseron

Sep 24, 2008
Bayer HealthCare Pharmaceuticals Inc. will be launching a new 30-gauge needle (the same size used for insulin and pediatric injections) and new optional autoinjector (BETAJECT® LITE) at the end of October. The new autoinjector will replace all previous autoinjectors; use of any autoinjector other than this latest version may result in people not receiving their full dose of medication. People who are currently taking Betaseron can log onto www.betaseron.com/thinner or call BETAPLUS at 1-800-788-1467 for more information about the new needle and to request the new autoinjector.

New Recommendations from the FDA Concerning the Monitoring of Cardiac Function in People Taking Mitoxantrone

Aug 11, 2008
In July 2008, the FDA issued new recommendations for cardiac monitoring of people taking mitoxantrone (marketed as Novantrone® by EMD Serono and also available in generic form). In addition to the earlier recommendation that left ventricular ejection fraction (LVEF) be evaluated before initiating treatment and prior to the administration of each dose, the FDA further recommends that all patients with MS who have completed treatment with mitoxantrone receive yearly quantitative LVEF evaluations to detect late-occurring cardiac toxicity.

Two New Cases of PML Develop in People with MS Taking Tysabri

Aug 01, 2008
UPDATE: As of December 15, 2008, four cases of PML have been reported since the drug was made commercially available. Read more about the first two cases, reported in August.

Previous Report of Two Cases of Melanoma (Skin Cancer) Reported in People Taking Tysabri for MS Updated with Company Rebuttal

Jul 02, 2008
Physicians in Boston have reported two cases of melanoma (skin cancer) that developed in women in their practice who were administered Tysabri® (natalizumab, Biogen Idec and Elan Pharmaceuticals) to treat their multiple sclerosis. In a letter to the editor published in the July 3, 2008 issue of the New England Journal of Medicine (2008; 359[1]:99-100), Dr. Michael A. Panzara and other representatives of Biogen Idec, Inc., pointed out that individual case reports, such as were reported by Dr. Mullen and colleagues, do not provide an adequate basis for proving cause and effect.

Low Dose Naltrexone Update

Jun 02, 2008
We have received a number of inquiries about the use of low dose naltrexone (LDN) as a treatment for multiple sclerosis. There are currently no published data from controlled clinical trials to support the use of naltrexone in MS. Further study is needed to determine if this is a safe and effective treatment for people with MS.

more treatment updates